@article{8252ef8098e349a894fb28cf5839d09f,
title = "Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies",
author = "Andrea Kokorovic and So, {Alan I.} and Hosam Serag and Christopher French and Hamilton, {Robert J.} and Izard, {Jason P.} and Nayak, {Jasmir G.} and Fr{\'e}deric Pouliot and Fred Saad and Bobby Shayegan and Armen Aprikian and Rendon, {Ricardo A.}",
note = "Funding Information: Competing interests: Dr. So has been an advisory board member for AbbVie, Amgen, Astellas, Bayer, Janssen, Ferring, and TerSera; and has participated in clinical trials supported by Astellas, Ferring, and Janssen. Dr. Izard has received a grant(s) or honoraria from AbbVie, Astellas, Bayer, Ferring, Janssen, and Sanofi; and has participated in clinical trials supported by AbbVie, Astellas, AstraZeneca, Bayer, Janssen, and Merck. Dr. Saad has been an advisory board member for and has received payment/honoraria from AbbVie, Amgen, Astellas, Bayer, Janssen, and Sanofi; and has participated in clinical trials supported by Amgen, Astellas, Bayer, Janssen, and Sanofi. Dr. Shayegan has been an advisory board member for Astellas, Bayer, and Janssen; and has received a research grant from Janssen. Dr. Aprikian has been an advisory board member for AbbVie, Astellas, and Bayer; and has received grants from AbbVie, Astellas Bayer, Sanofi, and TerSera. Dr. Rendon has been an advisory board and speakers{\textquoteright} bureau member for and has received honoraria from AbbVie, Amgen, Astellas, AstraZeneca, Bayer, Ferring, Jansen, and Sanofi. The remaining authors report no competing personal or financial interests related to this work.",
year = "2021",
month = apr,
day = "21",
doi = "10.5489/CUAJ.7355",
language = "English",
volume = "15",
pages = "1--36",
journal = "Journal of the Canadian Urological Association",
issn = "1911-6470",
publisher = "Canadian Medical Association",
number = "6",
}